Barua Lab
The Barua lab has garnered international profile on the basis of their unique genetic observations and ongoing efforts to establish biologic mechanism linking gene mutations to chronic kidney disease. The Barua lab’s goal is to improve diagnosis and by defining the genetic basis of clinical syndromes previously labelled as idiopathic, to have important impact on therapeutic development.
About Us
A major contribution of the Barua Lab has been the identification of variants in the α3, α4 and α5 chains of type IV collagen in hematuria, albuminuria and a pathologic lesion known as focal and segmental glomerulosclerosis (FSGS). The Barua lab has also identified PAX2 mutations in FSGS. These findings form the basis of mechanistic work that the group is now pursuing alongside their human genetic studies.
Leadership
Awards
-
2021-24
Clinician Scientist Merit Award
Awarded by the Department of Medicine, University of Toronto.
-
2021
Mimi and Charles Hollenberg Research Award
This award is named after Dr. Charles Hollenberg, whose legacy in academic medical research still impacts lives today.
-
2018-19
Mimi and Charles Hollenberg Research Award, Category 2 (Clinical Epidemiology), Second Place: Khalil Udwan - Under Supervision of Dr. Barua
This award is named after Dr. Charles Hollenberg, whose legacy in academic medical research still impacts lives today.
-
2016-19
KRESCENT Award
Awarded by the Canadian Institutes of Health Research and Kidney Foundation of Canada.
-
2016
1st Place - Great Cases in Medicine Competition
Awarded by University Health Network and Mount Sinai Hospital.
-
2009
Mimi and Charles Hollenberg Research Award, Category 2 (Clinical Epidemiology)
Award named after Dr. Charles Hollenberg, whose legacy in academic medical research still impacts lives today.
Publications
-
2023
Quantifying the Benefits of Remission Duration in Focal and Segmental Glomerulosclerosis -
2023
Alport Syndrome: Clinical Spectrum and Therapeutic Advances -
2022
GWAS of Hematuria